GE HealthCare Technologies Inc. has announced a wave of transformative innovations in healthcare that will be showcased at the upcoming RSNA 2025 conference. The company highlighted its significant investment of over $3 billion in research and development since 2022, resulting in advancements across smart devices, radiopharmaceuticals, and AI-enabled solutions. GE HealthCare currently leads the industry with 100 FDA-authorized AI-enabled medical device solutions, aimed at transforming clinical workflows and supporting rapid, precise decision-making. Among its recent breakthroughs is Flyrcado, a first-of-its-kind PET molecular imaging agent for diagnosing and assessing coronary artery disease, marking a major innovation in nuclear cardiology. These results and innovations will be presented at RSNA 2025.